Table 1. Patient and tumor characteristics.
| Characteristic | Basic cohort (n = 102) | Validation cohort (n = 41) |
| Histology (n) | ||
| Squamous | 96 | 40 |
| Adenocarcinoma | 1 | 0 |
| Adenosquamous carcinoma | 5 | 1 |
| HPV status (n)a , b | ||
| HPV16 | 65 | 35 |
| HPV18 | 7 | 0 |
| HPV16+18 | 11 | 1 |
| HPV other | 10 | 4 |
| HPV negative | 8 | 1 |
| FIGO stage (n) | ||
| 1B | 6 | 2 |
| 2 | 57 | 27 |
| 3 | 35 | 9 |
| 4A | 4 | 3 |
| Tumor sizec: vol (cm3)d, diameter (cm)e | ||
| Median | 45.1, 4.4 | 36.6, 4.1 |
| Range | 2.8–321, 1.8–8.5 | 8.7–192, 2.5–7.2 |
| Pelvic lymph node statusc (n) | ||
| Positive | 37 | 12 |
| Negative | 65 | 29 |
| Age (years) | ||
| Median | 56 | 55 |
| Range | 28–85 | 25–81 |
| Observation time (months) | ||
| Median | 42 | 31 |
| Range | 21–71 | 24–46 |
| Relapse | 32 | 12 |
a
PCR on DNA was performed, using the primers listed in [9]. The products were detected by polyacrylamide gel electrophoresis or the Agilent DNA 1000 kit (Agilent Technologies Inc., Germany).
b
HPV status was not determined for one patient in the basic cohort due to lack of DNA for analysis.
c
Tumor size and lymph node status were determined from pretreatment magnetic resonance (MR) images.
d
Volume was calculated based on 3 orthogonal diameters (a,b,c) as (π/6)*abc.
e
Diameter was calculated from tumor volume (4π/3)*r3.